
Kyung Hyung Park-Min

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2494552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of <scp>Lysineâ€Specific</scp> Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through <scp>Hypoxiaâ€Inducible</scp> Factor 1α and <scp>E2F1</scp> . Arthritis and Rheumatology, 2022, 74, 948-960.	5.6	20
2	Distinct Inflammatory Macrophage Populations Sequentially Infiltrate Boneâ€toâ€Tendon Interface Tissue After Anterior Cruciate Ligament (<scp>ACL)</scp> Reconstruction Surgery in Mice. JBMR Plus, 2022, 6,	2.7	9
3	THOC5 regulates human osteoclastogenesis. European Journal of Cell Biology, 2022, 101, 151248.	3.6	0
4	Regulation of Osteoclast Differentiation and Activity by Lipid Metabolism. Cells, 2021, 10, 89.	4.1	41
5	MYC-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF4 in inflammatory macrophages. Cell Reports, 2021, 35, 109264.	6.4	30
6	MEF2C regulates osteoclastogenesis and pathologic bone resorption via c-FOS. Bone Research, 2021, 9, 4.	11.4	28
7	Glucocorticoidâ€induced osteonecrosis in systemic lupus erythematosus patients. Clinical and Translational Medicine, 2021, 11, e526.	4.0	10
8	Augmenting MNK1/2 activation by c-FMS proteolysis promotes osteoclastogenesis and arthritic bone erosion. Bone Research, 2021, 9, 45.	11.4	5
9	NRF2 Is an Upstream Regulator of MYC-Mediated Osteoclastogenesis and Pathological Bone Erosion. Cells, 2020, 9, 2133.	4.1	9
10	The M-CSF receptor in osteoclasts and beyond. Experimental and Molecular Medicine, 2020, 52, 1239-1254.	7.7	104
11	Nuclear receptors in osteoclasts. Current Opinion in Pharmacology, 2020, 53, 8-17.	3.5	3
12	Sexual Dimorphism in Differentiating Osteoclast Precursors Demonstrates Enhanced Inflammatory Pathway Activation in Female Cells. Journal of Bone and Mineral Research, 2020, 36, 1104-1116.	2.8	19
13	The Cytokine TNF Promotes Transcription Factor SREBP Activity and Binding to Inflammatory Genes to Activate Macrophages and Limit Tissue Repair. Immunity, 2019, 51, 241-257.e9.	14.3	91
14	IFN-Î ³ selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation. Nature Communications, 2019, 10, 3320.	12.8	71
15	Metabolic reprogramming in osteoclasts. Seminars in Immunopathology, 2019, 41, 565-572.	6.1	90
16	Insights into rheumatic diseases from next-generation sequencing. Nature Reviews Rheumatology, 2019, 15, 327-339.	8.0	28
17	Mechanisms involved in normal and pathological osteoclastogenesis. Cellular and Molecular Life Sciences, 2018, 75, 2519-2528.	5.4	71
18	Epigenetic regulation of bone cells. Connective Tissue Research, 2017, 58, 76-89.	2.3	27

Kyung Hyung Park-Min

#	Article	IF	CITATIONS
19	Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nature Immunology, 2017, 18, 1104-1116.	14.5	204
20	Hypoxia-Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis. Immunity, 2017, 47, 66-79.e5.	14.3	71
21	Interferon-Î ³ Represses M2 Gene Expression in Human Macrophages by Disassembling Enhancers Bound by the Transcription Factor MAF. Immunity, 2017, 47, 235-250.e4.	14.3	153
22	MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα. Journal of Clinical Investigation, 2017, 127, 2555-2568.	8.2	84
23	Increased Ca2+ signaling through CaV1.2 promotes bone formation and prevents estrogen deficiency–induced bone loss. JCI Insight, 2017, 2, .	5.0	38
24	Intravenous Immunoglobulin (IVIG) Attenuates TNFâ€Induced Pathologic Bone Resorption and Suppresses Osteoclastogenesis by Inducing A20 Expression. Journal of Cellular Physiology, 2016, 231, 449-458.	4.1	12
25	Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8. Journal of Immunology, 2016, 196, 4452-4456.	0.8	66
26	Opposing regulation of the late phase TNF response by mTORC1-IL-10 signaling and hypoxia in human macrophages. Scientific Reports, 2016, 6, 31959.	3.3	26
27	Tmem178 acts in a novel negative feedback loop targeting NFATc1 to regulate bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15654-15659.	7.1	26
28	Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nature Communications, 2014, 5, 5418.	12.8	103
29	Negative regulation of osteoclast precursor differentiation by CD11b and \hat{l}^2 2 integrin-B-cell lymphoma 6 signaling. Journal of Bone and Mineral Research, 2013, 28, 135-149.	2.8	52
30	Tumor Necrosis Factor α Induces Sustained Signaling and a Prolonged and Unremitting Inflammatory Response in Rheumatoid Arthritis Synovial Fibroblasts. Arthritis and Rheumatism, 2013, 65, 928-938.	6.7	119
31	iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. Journal of Clinical Investigation, 2013, 123, 928-32.	8.2	129
32	ITAM-Coupled Receptors Inhibit IFNAR Signaling and Alter Macrophage Responses to TLR4 and <i>Listeria mono cytogenes</i> . Journal of Immunology, 2012, 188, 3447-3457.	0.8	24
33	Tumor necrosis factor induces GSK3 kinase–mediated cross-tolerance to endotoxin in macrophages. Nature Immunology, 2011, 12, 607-615.	14.5	160
34	Feedback inhibition of osteoclastogenesis during inflammation by ILâ€10, Mâ€CSF receptor shedding, and induction of IRF8. Annals of the New York Academy of Sciences, 2011, 1237, 88-94.	3.8	27
35	Interleukinâ€27 inhibits human osteoclastogenesis by abrogating RANKLâ€mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis and Rheumatism, 2010, 62, 402-413.	6.7	64
36	Direct Inhibition of Human RANK+ Osteoclast Precursors Identifies a Homeostatic Function of IL-1β. Journal of Immunology, 2010, 185, 5926-5934.	0.8	42

#	Article	IF	CITATIONS
37	IL-10 Suppresses Calcium-Mediated Costimulation of Receptor Activator NF-κB Signaling during Human Osteoclast Differentiation by Inhibiting TREM-2 Expression. Journal of Immunology, 2009, 183, 2444-2455.	0.8	103
38	Inhibition of RANK Expression and Osteoclastogenesis by TLRs and IFN-Î ³ in Human Osteoclast Precursors. Journal of Immunology, 2009, 183, 7223-7233.	0.8	140
39	Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. Human Immunology, 2009, 70, 211-217.	2.4	87
40	'Tuning' of type I interferon–induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nature Immunology, 2008, 9, 186-193.	14.5	74
41	TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon–response genes. Nature Immunology, 2008, 9, 378-387.	14.5	388
42	Regulation of STAT pathways and IRF1 during human dendritic cell maturation by TNF-α and PGE2. Journal of Leukocyte Biology, 2008, 84, 1353-1360.	3.3	28
43	FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin. Immunity, 2007, 26, 67-78.	14.3	147
44	Apoptotic Cells Inhibit LPS-Induced Cytokine and Chemokine Production and IFN Responses in Macrophages. Human Immunology, 2007, 68, 156-164.	2.4	46
45	IFN-Î ³ -Primed Macrophages Exhibit Increased CCR2-Dependent Migration and Altered IFN-Î ³ Responses Mediated by Stat1. Journal of Immunology, 2005, 175, 3637-3647.	0.8	57
46	Regulation of macrophage phenotype by long-term exposure to IL-10. Immunobiology, 2005, 210, 77-86.	1.9	57
47	Kinetics of IL-10-induced gene expression in human macrophages. Immunobiology, 2005, 210, 87-95.	1.9	25
48	Inhibition of Interleukin 10 Signaling after Fc Receptor Ligation and during Rheumatoid Arthritis. Journal of Experimental Medicine, 2003, 197, 1573-1583.	8.5	72